Profusa, Inc.
Close on Oct 19, 2026
- Market cap
- $51.92K
- P/E (TTM)
- –
- Dividend yield
- –
About Profusa
Surgical & Medical Instruments & Apparatus, SIC 3841
Profusa, Inc. is a digital health technology company developing a continuous biochemical sensor platform for monitoring individual biochemistry in real time. The platform integrates passive, subcutaneous hydrogel biosensors with wearable, rechargeable optical readers and mobile data algorithms to track physiological biomarkers. Its lead product candidates include Lumee Oxygen, designed to monitor dissolved tissue oxygen for managing wound care and peripheral arterial disease in critical limb ischemia patients, and Lumee Glucose, a continuous glucose monitoring platform designed for individuals with diabetes. The technology serves patients and healthcare professionals in clinical, surgical, and ambulatory settings.
The company operates primarily within the digital health and remote monitoring sectors, targeting clinical needs across the United States and the European Union while collaborating with investment partners to access Asia Pacific markets. Profusa maintains corporate headquarters and principal executive offices in Berkeley, California.
Summary of the business section of Profusa's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Profusa, Inc.
- Headquarters
- New York, NY
- Address
- 207 West 25th St, 9th Floor 10001
- Phone
- (212) 494-9022
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, San Francisco, CA
Stock & identifiers
- Ticker
- PFSA
- Other tickers
- NVACW
- Exchange
- Nasdaq
- IPO date
- Dec 22, 2021
- Shares outstanding
- 1M, Aug 18, 2026
- Public float
- $1.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-4 reverse, Aug 17, 2026; 1-for-25 reverse, Jul 7, 2026; 1-for-75 reverse, Feb 9, 2026; 1-for-2.67 reverse, Nov 19, 2025
- SEC CIK
- 1859807
- CUSIP
- 74319X116
- ISIN
- US74319X1164
- EIN
- 86-3437271
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ben Chung-Bin Hwang | Chief Executive Officer, Director | 844,228 |
| Fred S. Knechtel | Chief Financial Officer | 54,470 |
| Jack E. Stover | Chief Executive Officer | 32,091 |
| Lauren Chung | Director | 30,000 |
| Peter O'Rourke | Director | 107,750 |
| Rajesh Asarpota | Director | – |
Corporate history
Events identified from SEC filings